Angiotensin II Blockade Reverses Myocardial Fibrosis in a Transgenic Mouse Model of Human Hypertrophic Cardiomyopathy
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Background —Hypertrophic cardiomyopathy (HCM), the most common cause of sudden cardiac death in the young, is characterized by cardiac hypertrophy, myocyte disarray, and interstitial fibrosis. We propose that hypertrophy and fibrosis are secondary to the activation of trophic and mitotic factors and, thus, potentially reversible. We determined whether the blockade of angiotensin II, a known cardiotrophic factor, could reverse or attenuate interstitial fibrosis in a transgenic mouse model of human HCM. Methods and Results —We randomized 24 adult cardiac troponin T (cTnT-Q 92 ) mice, which exhibit myocyte disarray and interstitial fibrosis, to treatment with losartan or placebo and included 12 nontransgenic mice as controls. The mean dose of losartan and the mean duration of therapy were 14.2±5.3 mg · kg –1 · d –1 and 42±9.6 days, respectively. Mean age, number of males and females, and heart/body weight ratio were similar in the groups. Collagen volume fraction and extent of myocyte disarray were increased in the cTnT-Q 92 mice (placebo group) compared with nontransgenic mice (9.9±6.8% versus 4.5±2.2%, P =0.01, and 27.6±10.6% versus 3.9±2.3%, P <0.001, respectively). Treatment with losartan reduced collagen volume fraction by 49% to 4.9±2.9%. The expression of collagen 1α (I) and transforming growth factor-β1, a mediator of angiotensin II profibrotic effect, were also reduced by 50%. Losartan had no effect on myocyte disarray. Conclusions —Treatment with losartan reversed interstitial fibrosis and the expression of collagen 1α (I) and transforming growth factor-β1 in the hearts of cTnT-Q 92 mice. These findings suggest that losartan has the potential to reverse or attenuate interstitial fibrosis, a major predictor of sudden cardiac death, in human patients with HCM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sudden Death in Young Competitive Athletes: Clinical, Demographic, and Pathological Profiles
Maron, B. J. (1996) · JAMA · doi:10.1001/jama.1996.03540030033028 · Cited by 1,693
Magnitude of Left Ventricular Hypertrophy and Risk of Sudden Death in Hypertrophic Cardiomyopathy
Spirito, P., Bellone, P., Harris, K. M., Bernabò, P., Bruzzi, P., & Maron, B. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006153422403 · Cited by 1,143
Lisinopril-Mediated Regression of Myocardial Fibrosis in Patients With Hypertensive Heart Disease
Brilla, C. G., Funck, R. C., & Rupp, H. (2000) · Circulation · doi:10.1161/01.cir.102.12.1388 · Cited by 649
Shirani, J., Pick, R., Roberts, W. C., & Maron, B. J. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00492-1 · Cited by 408
Maron, B. J., & Roberts, W. C. (1979) · Circulation · doi:10.1161/01.cir.59.4.689 · Cited by 366
Angiotensin II Has Multiple Profibrotic Effects in Human Cardiac Fibroblasts
Kawano, H., Do, Y. S., Kawano, Y., Starnes, V., Barr, M., Law, R. E., & Hsueh, W. A. (2000) · Circulation · doi:10.1161/01.cir.101.10.1130 · Cited by 312
Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy
Marian, A. (2000) · The Lancet · doi:10.1016/s0140-6736(99)06187-5 · Cited by 235
Self-citationLi, R.-K., Li, G., Mickle, D. A. G., Weisel, R. D., Merante, F., Luss, H., Rao, V., Christakis, G. T., & Williams, W. G. (1997) · Circulation · doi:10.1161/01.cir.96.3.874 · Cited by 211
Tomita, H., Egashira, K., Ohara, Y., Takemoto, M., Koyanagi, M., Katoh, M., Yamamoto, H., Tamaki, K., Shimokawa, H., & Takeshita, A. (1998) · Hypertension · doi:10.1161/01.hyp.32.2.273 · Cited by 192
Oberst, L., Zhao, G., Park, J. T., Brugada, R., Michael, L. H., Entman, M. L., Roberts, R., & Marian, A. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci4088 · Cited by 116
Self-citation
Cited by
Hypertrophic Cardiomyopathy: A Systematic Review
Maron, B. J. (2002) · JAMA · doi:10.1001/jama.287.10.1308 · Cited by 2,224
Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome
Habashi, J. P., Judge, D. P., Holm, T. M., Cohn, R. D., Loeys, B. L., Cooper, T. K., Myers, L., Klein, E. C., Liu, G., Calvi, C., et al. (2006) · Science · doi:10.1126/science.1124287 · Cited by 1,794
Maron, B. J., McKenna, W. J., Danielson, G. K., Kappenberger, L. J., Kuhn, H. J., Seidman, C. E., Shah, P. M., Spencer, W. H., Spirito, P., Ten Cate, F. J., et al. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00941-0 · Cited by 1,578
The pathogenesis of cardiac fibrosis
Kong, P., Christia, P., & Frangogiannis, N. G. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1349-6 · Cited by 1,567
Targeting the TGFβ signalling pathway in disease
Akhurst, R. J., & Hata, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3810 · Cited by 1,466
Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy
Marian, A. J., & Braunwald, E. (2017) · Circulation Research · doi:10.1161/circresaha.117.311059 · Cited by 1,403
Self-citationAngiotensin II Blockade and Aortic-Root Dilation in Marfan's Syndrome
Brooke, B. S., Habashi, J. P., Judge, D. P., Patel, N., Loeys, B., & Dietz, H. C. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706585 · Cited by 843
Diop-Frimpong, B., Chauhan, V. P., Krane, S., Boucher, Y., & Jain, R. K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018892108 · Cited by 733
“As a result, losartan and other RAAS inhibitors can reduce the levels of collagen I and III and basement membrane collagen IV in various experimental models of fibrosis (31, 32) and reverse renal and cardiac fibrosis in hypertensive patients (33, 34).”
BackgroundMaron, B. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00479-2 · Cited by 698
Cohn, R. D., van Erp, C., Habashi, J. P., Soleimani, A. A., Klein, E. C., Lisi, M. T., Gamradt, M., ap Rhys, C. M., Holm, T. M., Loeys, B. L., et al. (2007) · Nature Medicine · doi:10.1038/nm1536 · Cited by 669
Role of innate and adaptive immune mechanisms in cardiac injury and repair
Epelman, S., Liu, P. P., & Mann, D. L. (2015) · Nature Reviews Immunology · doi:10.1038/nri3800 · Cited by 634
Nagueh, S. F., Bachinski, L. L., Meyer, D., Hill, R., Zoghbi, W. A., Tam, J. W., Quiñones, M. A., Roberts, R., & Marian, A. J. (2001) · Circulation · doi:10.1161/01.cir.104.2.128 · Cited by 616
Self-citationTeekakirikul, P., Eminaga, S., Toka, O., Alcalai, R., Wang, L., Wakimoto, H., Nayor, M., Konno, T., Gorham, J. M., Wolf, C. M., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42028 · Cited by 448
Milewicz, D. M., Guo, D.-C., Tran-Fadulu, V., Lafont, A. L., Papke, C. L., Inamoto, S., Kwartler, C. S., & Pannu, H. (2008) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.8.080706.092303 · Cited by 404
Bos, J. M., Towbin, J. A., & Ackerman, M. J. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.075 · Cited by 396
Patel, R., Nagueh, S. F., Tsybouleva, N., Abdellatif, M., Lutucuta, S., Kopelen, H. A., Quinones, M. A., Zoghbi, W. A., Entman, M. L., Roberts, R., et al. (2001) · Circulation · doi:10.1161/01.cir.104.3.317 · Cited by 357
Self-citationCardiac fibrosis: new insights into the pathogenesis
Ma, Z.-G., Yuan, Y.-P., Wu, H.-M., Zhang, X., & Tang, Q.-Z. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.28103 · Cited by 331
Clinical and Mechanistic Insights Into the Genetics of Cardiomyopathy
Burke, M. A., Cook, S. A., Seidman, J. G., & Seidman, C. E. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.08.079 · Cited by 325
THE GENETIC BASIS FOR CARDIAC REMODELING
Ahmad, F., Seidman, J. G., & Seidman, C. E. (2005) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.6.080604.162132 · Cited by 307
The Case for Myocardial Ischemia in Hypertrophic Cardiomyopathy
Maron, M. S., Olivotto, I., Maron, B. J., Prasad, S. K., Cecchi, F., Udelson, J. E., & Camici, P. G. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.072 · Cited by 307
Milewicz, D. M., Braverman, A. C., De Backer, J., Morris, S. A., Boileau, C., Maumenee, I. H., Jondeau, G., Evangelista, A., & Pyeritz, R. E. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00298-7 · Cited by 305
Pannu, H., Tran-Fadulu, V., Papke, C. L., Scherer, S., Liu, Y., Presley, C., Guo, D., Estrera, A. L., Safi, H. J., Brasier, A. R., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm201 · Cited by 293
Self-citationNagueh, S. F., McFalls, J., Meyer, D., Hill, R., Zoghbi, W. A., Tam, J. W., Quiñones, M. A., Roberts, R., & Marian, A. J. (2003) · Circulation · doi:10.1161/01.cir.0000084500.72232.8d · Cited by 276
Self-citationHANNA, N. (2004) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.03.026 · Cited by 275
Losartan prevents acquired epilepsy via TGF‐β signaling suppression
Bar‐Klein, G., Cacheaux, L. P., Kamintsky, L., Prager, O., Weissberg, I., Schoknecht, K., Cheng, P., Kim, S. Y., Wood, L., Heinemann, U., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24147 · Cited by 270
Molecular Genetic Basis of Hypertrophic Cardiomyopathy
Marian, A. J. (2021) · Circulation Research · doi:10.1161/circresaha.121.318346 · Cited by 250
Self-citationMechanisms of disease: hypertrophic cardiomyopathy
Frey, N., Luedde, M., & Katus, H. A. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.159 · Cited by 235
Oller, J., Méndez-Barbero, N., Ruiz, E. J., Villahoz, S., Renard, M., Canelas, L. I., Briones, A. M., Alberca, R., Lozano-Vidal, N., Hurlé, M. A., et al. (2017) · Nature Medicine · doi:10.1038/nm.4266 · Cited by 177
Nanoparticle-based hyperthermia, a local treatment modulating the tumor extracellular matrix
Kolosnjaj-Tabi, J., Marangon, I., Nicolas-Boluda, A., Silva, A. K. A., & Gazeau, F. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.07.010 · Cited by 86
Genetics and Genomics of Single-Gene Cardiovascular Diseases
Marian, A. J., van Rooij, E., & Roberts, R. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.09.968 · Cited by 48
Self-citationJosowitz, R., Mulero-Navarro, S., Rodriguez, N. A., Falce, C., Cohen, N., Ullian, E. M., Weiss, L. A., Rauen, K. A., Sobie, E. A., & Gelb, B. D. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.07.018 · Cited by 45
Chen, P., Yang, F., Wang, W., Li, X., Liu, D., Zhang, Y., Yin, G., Lv, F., Guo, Z., Mehta, J. L., et al. (2021) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248420942007 · Cited by 31
“Losartan effectively reverses myocardial fibrosis in the murine hypertensive models.(37,38) Based on the similarity of actions of losartan and liraglutide, it may be concluded that liraglutide acts as an anti-fibrosis drug works in part by inhibiting AT1R-ROS axis.”
Background
Metadata
- Authors
- Lim, D.-S., Lutucuta, S., Bachireddy, P., Youker, K., Evans, A., Entman, M., Roberts, R., & Marian, A. J.
- Venue
- Circulation
- Published
- 2001-02-13
- Volume
- 103
- Issue
- 6
- Pages
- 789-791
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W1995538993
- Cited by
- 386
- References
- 11
- FWCI
- 11.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.